Cancers, Vol. 13, Pages 332: CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
Cancers, Vol. 13, Pages 332: CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
Cancers doi: 10.3390/cancers13020332
Authors:
Michela Roberto
Antonio Astone
Andrea Botticelli
Luisa Carbognin
Alessandra Cassano
Giuliana D’Auria
Agnese Fabbri
Alessandra Fabi
Teresa Gamucci
Eriseld Krasniqi
Mauro Minelli
Armando Orlandi
Francesco Pantano
Ida Paris
Laura Pizzuti
Ilaria Portarena
Nello Salesi
Simone Scagnoli
Paola Scavina
Giuseppe Tonini
Patrizia Vici
Paolo Marchetti
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common breast cancer subtype, and endocrine therapy (ET) remains its therapeutic backbone. Although anti-estrogen therapies are usually effective initially, approximately 50% of HR+ patients develop resistance to ET within their lifetime, ultimately leading to disease recurrence and limited clinical benefit. The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to ET have remarkably improved the outcome of patients with HR+ advanced breast cancer (ABC) compared with anti-estrogens alone, by targeting the cell-cycle machinery and overcoming some aspects of endocrine resistance. However, which patients are the better candidates for these drugs, which are the mai...
Source: Cancers - Category: Cancer & Oncology Authors: Michela Roberto Antonio Astone Andrea Botticelli Luisa Carbognin Alessandra Cassano Giuliana D ’Auria Agnese Fabbri Alessandra Fabi Teresa Gamucci Eriseld Krasniqi Mauro Minelli Armando Orlandi Francesco Pantano Ida Paris Laura Pizzuti Ilaria Portarena Tags: Review Source Type: research